DOJ recovered $2.5 billion in 2018 healthcare false claim cases
According to the DOJ, this is the ninth consecutive year that the organizations' civil healthcare fraud settlements and judgments have exceeded $2 billion.
Abbott Laboratories’ bittersweet week
Despite the week ending on a high note for Abbott Laboratories with an amended $5.3 billion deal to buy Alere, a warning letter from the U.S. Food and Drug Administration drew attention to issues at another Abbott acquisition — St. Jude Medical.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
In move to nix $5.8B Alere deal, is Abbott shrewdly aiming to lower price tag?
Abbott wants out of its plan to buy Alere for $5.8 billion, but the point-of-care testing company is a perfect fit for Abbott, an analyst believes.
Alere under Medicare/Medicaid fraud investigation (updated)
The investigation into potential fraud could put the brakes on the planned multibillion-dollar acquisition of Alere by Abbott Laboratories.
Morning Read: Sanofi makes $9.3B offer for Medivation, Alere says it rejected Abbott’s request to scrap M&A deal
Also, Color Genomics expands its genetic test portfolio and Apple rolls out first clinical apps developed with CareKit.
Abbott is on a roll with acquisitions – next on the list: Kalila Medical
Abbott is taking the new year by storm with two acquisitions in two days. We'll see what company will be snatched up next.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Abbott agrees to put in nearly $6B to acquire Alere, broadening its diagnostics footprint
Abbott is looking to vastly expand its point-of-care diagnotics options by acquiring Alere.
Morning Read: Could Google searches help the FDA learn about drug side effects? ProNAi ‘s $138M IPO
Google met with FDA to discuss a paper on using search data to identify drug side effects and biotech company ProNAi has raised $138M in an IPO.
5 ways health IT companies are easing the transition from fee for service to pay for performance
As hospitals face increased pressure from the Affordable Care Act to move toward a reimbursement model centered in value-based outcomes integrated health systems are positioned to take advantage of some of the more sophisticated analytical tools to improve care coordination. There were an abundance of population health tools at HIMSS — from care coordination to […]